DarioHealth ( (DRIO) ) has released its Q3 earnings. Here is a breakdown of the information DarioHealth presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
DarioHealth Corp. is a company specializing in digital therapeutics, providing personalized, data-driven health solutions across various conditions such as diabetes, hypertension, and behavioral health. Operating primarily in the healthcare technology sector, it leverages advanced software and coaching to enhance individual health management.
The latest earnings report from DarioHealth indicates ongoing financial challenges despite growth in certain areas. The company, which has been consistently operating at a loss, reported a net loss of $33.1 million for the nine months ended September 30, 2024. This is an improvement from the $45.1 million loss in the same period of 2023, indicating some financial progress.
Key financial metrics show that DarioHealth’s revenues increased to $19.4 million for the first nine months of 2024, up from $16.7 million in the previous year. The growth was driven by both service and consumer hardware sales. Meanwhile, operating expenses rose due to increased investments in research and development and sales and marketing efforts. The acquisition of Twill, a company with a focus on mental health solutions, is expected to enhance DarioHealth’s product offerings and contribute to future revenue growth.
The company’s management remains focused on transitioning to profitability through strategic acquisitions and partnerships. Despite the current financial strain, they believe that their comprehensive health management platform positions them well for future growth. DarioHealth plans to continue developing new products and expanding its market reach to achieve long-term financial sustainability.
